A trial to evaluate ZD1839 (IRESSA) [gefitinib] in combination with radiotherapy and gemcitabine as first-line treatment in patients with locally advanced pancreatic cancer

Trial Profile

A trial to evaluate ZD1839 (IRESSA) [gefitinib] in combination with radiotherapy and gemcitabine as first-line treatment in patients with locally advanced pancreatic cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2006

At a glance

  • Drugs Gefitinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2006 Status change
    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top